Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference
Friday, January 15, 2021, at 4:00 pm Pacific Time / 6:00 pm Central Time
News provided by
Share this article
Share this article
REDWOOD CITY, Calif., Dec. 22, 2020 /PRNewswire/ Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it will host and webcast a virtual investor briefing at the 2021 North American Neuromodulation Society (NANS) Virtual Conference on Friday, January 15, 2021, beginning at 4:00 pm PST / 6:00 pm CST. Nevro Chairman, CEO and President D. Keith Grossman will host the event and will provide a business update and answer questions from investors about the Company s latest developments. Nevro s Chief Medical Officer, David Caraway, MD, PhD, and Nevro s Chief Financial Officer, Rod MacLeod, will also participate in the event.
Share this article
Share this article
REDWOOD CITY, Calif., Dec. 15, 2020 /PRNewswire/ Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro s Chairman, CEO and President, will present at the 39
th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 4:30 pm Eastern Time / 1:30 pm Pacific Time.
A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro s website at www.nevro.com.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the Investor Relations section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
Nevro Announces Agreement to Conclude Its Patent Lawsuit in the Northern District of California Against Boston Scientific
News provided by
Share this article
REDWOOD CITY, Calif., Dec. 14, 2020 /PRNewswire/
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that, in its patent litigation against Boston Scientific, the parties agreed to the dismissal of the patent case filed by Nevro in the Northern District of California relating to high frequency paresthesia-free SCS therapy. The official dismissal of the case is subject to the approval of the court.